Clinical Trial Update: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs [Phase 2]

View source ↗

Summary

Phase 2 trial shows regression of fibrosis and reversal of diastolic dysfunction in heart failure with preserved ejection fraction after treatment with allogene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• CAP-1002 (cardiosphere-derived cells)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Congestive Heart Failure, Heart Failure, Diastolic | Phase 2 | Status: COMPLETED | Results posted: 2024-07-25